Holders — by stockHoldings — by fund
EcoR1 Capital, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001587114
$2.06B
disclosed book value
31
positions
29.2%
largest position share
Positions, as of 2026-06-30
top 33 of 31 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | ZYMEZYMEWORKS INC | 23.0M | $600.4M | 29.2% |
| 2 | ANABANAPTYSBIO INC | 7.9M | $531.9M | 25.9% |
| 3 | AKTSAKTIS ONCOLOGY INC | 4.8M | $155.5M | 7.6% |
| 4 | CGONCG ONCOLOGY INC | 1.5M | $106.2M | 5.2% |
| 5 | ETONETON PHARMACEUTICALS INC | 2.2M | $78.6M | 3.8% |
| 6 | CRISPR THERAPEUTICS AG | 1.4M | $75.8M | 3.7% |
| 7 | ORICORIC PHARMACEUTICALS INC | 6.7M | $72.9M | 3.5% |
| 8 | TRAXFIRST TRACKS BIOTHERAPEUTICS | 3.2M | $63.9M | 3.1% |
| 9 | LKFTLAKEFRONT BIOTHERAPEUTICS NV | 1.7M | $50.0M | 2.4% |
| 10 | NGNENEUROGENE INC | 1.3M | $40.0M | 1.9% |
| 11 | CGONCG ONCOLOGY INCCALL | 561,500 | $39.9M | 1.9% |
| 12 | STOKSTOKE THERAPEUTICS INC | 735,000 | $24.0M | 1.2% |
| 13 | FULCFULCRUM THERAPEUTICS INC | 6.5M | $24.0M | 1.2% |
| 14 | LEGNLEGEND BIOTECH CORP | 800,000 | $23.1M | 1.1% |
| 15 | BBOTBRIDGEBIO ONCOLOGY THERAPEUT | 2.8M | $21.5M | 1% |
| 16 | MBXMBX BIOSCIENCES INC | 388,500 | $21.4M | 1% |
| 17 | ZBIOZENAS BIOPHARMA INC | 789,500 | $20.0M | 1% |
| 18 | ATRAATARA BIOTHERAPEUTICS INC | 1.6M | $17.8M | 0.9% |
| 19 | RLAYRELAY THERAPEUTICS INC | 697,948 | $13.1M | 0.6% |
| 20 | AURAAURA BIOSCIENCES INC | 1.7M | $11.8M | 0.6% |
| 21 | ODTXODYSSEY THERAPEUTICS INC | 555,555 | $10.4M | 0.5% |
| 22 | EIKNEIKON THERAPEUTICS INC | 732,606 | $9.6M | 0.5% |
| 23 | PHARVARIS N V | 235,000 | $8.1M | 0.4% |
| 24 | ZURA BIO LTD | 1.2M | $7.0M | 0.3% |
| 25 | PHATPHATHOM PHARMACEUTICALS INC | 625,000 | $6.8M | 0.3% |
| 26 | NRIXNURIX THERAPEUTICS INC | 270,000 | $6.6M | 0.3% |
| 27 | ERASERASCA INC | 330,000 | $6.0M | 0.3% |
| 28 | ELOXELOXX PHARMACEUTICALS INC | 400,000 | $5.6M | 0.3% |
| 29 | AARDAARDVARK THERAPEUTICS INC | 396,194 | $2.3M | 0.1% |
| 30 | HELIX ACQUISITION CORP III USD | 200,000 | $2.1M | 0.1% |
| 31 | MREOMEREO BIOPHARMA GROUP PLC | 1.0M | $317,700 | 0% |
| 32 | SURROZEN INC | 4,444 | $115,322 | 0% |
| 33 | AARDAARDVARK THERAPEUTICS INCCALL | 14,700 | $84,672 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.